Cytosorbents
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 186
- Market Cap
- $56.6M
- Introduction
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.
CytoSorbents Announces Submission of DrugSorb-ATR Application to the FDA
CytoSorbents submitted DrugSorb-ATR De Novo marketing application to FDA for reducing perioperative bleeding in CABG surgery patients on ticagrelor. The FDA granted Breakthrough Device Designation. CytoSorbents also completed its Health Canada MDL application. Third quarter 2024 product sales are estimated at $8.3-$8.5 million, with expected regulatory decisions in 2025. The company anticipates normalized production levels and product gross margins in Q4 2024. Valuation estimates for 2024 and 2025 reflect cost controls and potential revenue growth.
© Copyright 2025. All Rights Reserved by MedPath